It Seems Sangamo Therapeutics, Inc. (SGMO) Will Go Up. Have Another Big Increase

April 17, 2018 - By Clifton Ray

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Logo

Investors sentiment decreased to 1.4 in 2017 Q4. Its down 0.17, from 1.57 in 2017Q3. It is negative, as 16 investors sold Sangamo Therapeutics, Inc. shares while 42 reduced holdings. 35 funds opened positions while 46 raised stakes. 53.22 million shares or 2.49% more from 51.93 million shares in 2017Q3 were reported.
Moreover, Sg Americas Securities Limited Liability Corporation has 0.01% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 44,444 shares. Ubs Asset Mgmt Americas holds 0% or 37,122 shares. Moreover, Swiss National Bank has 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 142,460 shares. Employees Retirement Association Of Colorado stated it has 25,992 shares or 0% of all its holdings. Ny State Common Retirement Fund stated it has 99,071 shares. Raymond James has invested 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Bnp Paribas Arbitrage Sa holds 0% or 17,055 shares in its portfolio. 37,809 were reported by Keybank National Association Oh. Rhenman Ptnrs Asset Mgmt Ab invested in 255,793 shares. Pacad Invest Limited has invested 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Guggenheim Capital Ltd Liability Co reported 128,715 shares or 0% of all its holdings. Jpmorgan Chase And invested in 0% or 20,951 shares. Hanson Mcclain stated it has 1,000 shares. Manufacturers Life Ins The owns 63,786 shares. Royal Commercial Bank Of Canada has 42,387 shares.

Since January 2, 2018, it had 0 insider purchases, and 13 sales for $2.30 million activity. Herberts Curt A. III also sold $41,684 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares. The insider Mento Steven J sold $219,546. Shares for $123,878 were sold by Conner Edward R. on Tuesday, March 6. Another trade for 9,450 shares valued at $235,080 was made by Ramasastry Saira on Monday, February 26.

The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is a huge mover today! The stock increased 9.08% or $1.625 during the last trading session, reaching $19.525. About 1.77 million shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 352.38% since April 17, 2017 and is uptrending. It has outperformed by 340.83% the S&P500.
The move comes after 8 months positive chart setup for the $1.69B company. It was reported on Apr, 17 by Barchart.com. We have $20.70 PT which if reached, will make NASDAQ:SGMO worth $101.16M more.

Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on May, 9. They expect $0.05 earnings per share, up 121.74 % or $0.28 from last year’s $-0.23 per share. SGMO’s profit will be $4.32M for 97.63 P/E if the $0.05 EPS becomes a reality. After $-0.15 actual earnings per share reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -133.33 % EPS growth.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Ratings Coverage

Among 7 analysts covering Sangamo Therapeutics (NASDAQ:SGMO), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Sangamo Therapeutics had 9 analyst reports since November 15, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, January 3 by Piper Jaffray. Wells Fargo maintained Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on Thursday, February 22 with “Buy” rating. Wedbush maintained Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on Wednesday, November 15 with “Hold” rating. Piper Jaffray maintained Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on Thursday, February 22 with “Buy” rating. The rating was maintained by Wedbush with “Hold” on Tuesday, March 13. As per Wednesday, November 15, the company rating was upgraded by PiperJaffray. The rating was maintained by Jefferies on Thursday, February 22 with “Buy”.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.69 billion. The company??s proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: